GoAI
Get started
Alterity Therapeutics Limited logo

Alterity Therapeutics Limited

ATHE

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.67

+$0.22 · +4.94%

Aug 21, 4:00 PM ET

ATHE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

61

Undervalued

Momentum

62

Gaining

Sentiment

56

Mixed

Risk resilience

48

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

Industry
Biotechnology
Sector
Healthcare
Headquarters
AU
CEO
David A. Stamler
Listed since
Sep 29, 2003
Employees
9

Market position

Day range

Current $4.67

52-week range

Current $4.67

Open
$4.59
Previous close
$4.45
Volume
10.17K
0.26× average
Average volume
39.42K
Average daily volume
Market cap
79.11M USD
Beta
-0.03
Market reference 1
50-day average
$4.8316
-3.34% below average
200-day average
$3.9603
+17.92% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
33.25M AUD
EV / EBITDA
-2.27×
Earnings yield
-18.33%
Free cash flow yield
-17.28%

Profitability & efficiency

Return on equity
-28.65%
Return on assets
-26.39%
Return on invested capital
-34.25%

Financial health

Current ratio
12.98×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends156%-78%-312%-546%Gross margin, FY2021: 91.70%Gross margin, FY2022: 92.88%Gross margin, FY2023: 92.72%Gross margin, FY2024: 94.67%Gross margin, FY2025: 97.66%Operating margin, FY2021: -349.77%Operating margin, FY2022: -302.56%Operating margin, FY2023: -373.72%Operating margin, FY2024: -487.69%Operating margin, FY2025: -267.96%Net margin, FY2021: -352.78%Net margin, FY2022: -250.75%Net margin, FY2023: -352.54%Net margin, FY2024: -475.79%Net margin, FY2025: -223.35%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 91.70%. Gross margin FY2022 92.88%. Gross margin FY2023 92.72%. Gross margin FY2024 94.67%. Gross margin FY2025 97.66%. Operating margin FY2021 -349.77%. Operating margin FY2022 -302.56%. Operating margin FY2023 -373.72%. Operating margin FY2024 -487.69%. Operating margin FY2025 -267.96%. Net margin FY2021 -352.78%. Net margin FY2022 -250.75%. Net margin FY2023 -352.54%. Net margin FY2024 -475.79%. Net margin FY2025 -223.35%.

Income trends

Revenue

5.44M AUD+35.32%

Operating income

−14.57M AUD+25.65%

Net income

−12.15M AUD+36.48%
Income trends across reported periods7.94M AUD−2.07M AUD−12.09M AUD−22.11M AUDRevenue, FY2021: 4.34M AUDRevenue, FY2022: 5.12M AUDRevenue, FY2023: 3.92M AUDRevenue, FY2024: 4.02M AUDRevenue, FY2025: 5.44M AUDOperating income, FY2021: −15.18M AUDOperating income, FY2022: −15.5M AUDOperating income, FY2023: −14.64M AUDOperating income, FY2024: −19.6M AUDOperating income, FY2025: −14.57M AUDNet income, FY2021: −15.31M AUDNet income, FY2022: −12.85M AUDNet income, FY2023: −13.81M AUDNet income, FY2024: −19.12M AUDNet income, FY2025: −12.15M AUDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.34M AUD. Revenue FY2022 5.12M AUD. Revenue FY2023 3.92M AUD. Revenue FY2024 4.02M AUD. Revenue FY2025 5.44M AUD. Operating income FY2021 −15.18M AUD. Operating income FY2022 −15.5M AUD. Operating income FY2023 −14.64M AUD. Operating income FY2024 −19.6M AUD. Operating income FY2025 −14.57M AUD. Net income FY2021 −15.31M AUD. Net income FY2022 −12.85M AUD. Net income FY2023 −13.81M AUD. Net income FY2024 −19.12M AUD. Net income FY2025 −12.15M AUD.
Metric (AUD)FY2025FY2024FY2023FY2022FY2021
Revenue5.44M AUD4.02M AUD3.92M AUD5.12M AUD4.34M AUD
Cost of goods sold127.52K AUD214.3K AUD285.07K AUD364.67K AUD360.03K AUD
Gross profit5.31M AUD3.8M AUD3.63M AUD4.76M AUD3.98M AUD
Research and development14.4M AUD18.64M AUD13.2M AUD14.75M AUD12.28M AUD
Selling, general, and administrative5.48M AUD4.76M AUD5.04M AUD5.51M AUD6.87M AUD
Operating expenses19.89M AUD23.41M AUD18.24M AUD20.26M AUD19.16M AUD
Interest income446.29K AUD268.42K AUD16.44K AUD2.5K AUD20.68K AUD
Depreciation and amortization28.31K AUD35.34K AUD37.85K AUD54.21K AUD18.66K AUD
Operating income−14.57M AUD−19.6M AUD−14.64M AUD−15.5M AUD−15.18M AUD
Net income−12.15M AUD−19.12M AUD−13.81M AUD−12.85M AUD−15.31M AUD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
71%
5 beats, 2 misses, 0 met estimates
Average EPS surprise
-39.60%
7 comparable reports
Latest EPS result
-0.38
Estimate -0.23 · Miss by 65.91%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0-0.19-0.38-0.58Q1 '24BeatQ2 '24No estimateQ3 '24BeatQ1 '25No estimateQ1 '25BeatQ3 '25BeatQ1 '26MissQ3 '26Estimate
Q1 2024, reported Feb 28, 2024: actual -0.003, estimate -0.105, surprise +97.53%, Beat. Q2 2024, reported Apr 11, 2024: actual -0.001, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual -0.002, estimate -0.053, surprise +96.21%, Beat. Q1 2025, reported Feb 3, 2025: actual -0.001, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 28, 2025: actual -0.001, estimate -0.533, surprise +99.87%, Beat. Q3 2025, reported Aug 28, 2025: actual -0.399, estimate -0.43, surprise +7.21%, Beat. Q1 2026, reported Feb 25, 2026: actual -0.383, estimate -0.231, surprise -65.91%, Miss. Q3 2026, reported Aug 28, 2026: actual —, estimate -0.122, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.4M3.79M2.17M549KQ1 '24BeatQ2 '24No estimateQ3 '24BeatQ1 '25No estimateQ1 '25MissQ3 '25MissQ1 '26MissQ3 '26Estimate
Q1 2024, reported Feb 28, 2024: actual 1.9M USD, estimate 958.26K USD, surprise +98.35%, Beat. Q2 2024, reported Apr 11, 2024: actual 1.06M USD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual 2.12M USD, estimate 950K USD, surprise +123.01%, Beat. Q1 2025, reported Feb 3, 2025: actual 802.96K USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 28, 2025: actual 802.96K USD, estimate 2.3M USD, surprise -65.14%, Miss. Q3 2025, reported Aug 28, 2025: actual 3.83M USD, estimate 5.05M USD, surprise -24.11%, Miss. Q1 2026, reported Feb 25, 2026: actual 645.88K USD, estimate 1.07M USD, surprise -39.60%, Miss. Q3 2026, reported Aug 28, 2026: actual —, estimate 2.32M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.00

49.89% upside
Past 12 months12-month forecastHigh $12.00Average $7.00Low $2.00

Corporate actions

Corporate action history

Stock split

Effective Jan 9, 2023

1:10

Stock split

Effective Mar 24, 2016

1:6

ATHE peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ATHE

research.disclaimer